Nature Communications (Jan 2019)
Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion
- Elisa Vergari,
- Jakob G. Knudsen,
- Reshma Ramracheya,
- Albert Salehi,
- Quan Zhang,
- Julie Adam,
- Ingrid Wernstedt Asterholm,
- Anna Benrick,
- Linford J. B. Briant,
- Margarita V. Chibalina,
- Fiona M. Gribble,
- Alexander Hamilton,
- Benoit Hastoy,
- Frank Reimann,
- Nils J. G. Rorsman,
- Ioannis I. Spiliotis,
- Andrei Tarasov,
- Yanling Wu,
- Frances M. Ashcroft,
- Patrik Rorsman
Affiliations
- Elisa Vergari
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Jakob G. Knudsen
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Reshma Ramracheya
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Albert Salehi
- Department of Physiology, Institute of Neuroscience and Physiology, University of Göteborg
- Quan Zhang
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Julie Adam
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Ingrid Wernstedt Asterholm
- Department of Physiology, Institute of Neuroscience and Physiology, University of Göteborg
- Anna Benrick
- Department of Physiology, Institute of Neuroscience and Physiology, University of Göteborg
- Linford J. B. Briant
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Margarita V. Chibalina
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Fiona M. Gribble
- Cambridge Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge School of Clinical Medicine
- Alexander Hamilton
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Benoit Hastoy
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Frank Reimann
- Cambridge Institute of Metabolic Science and MRC Metabolic Diseases Unit, University of Cambridge School of Clinical Medicine
- Nils J. G. Rorsman
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Ioannis I. Spiliotis
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Andrei Tarasov
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- Yanling Wu
- Department of Physiology, Institute of Neuroscience and Physiology, University of Göteborg
- Frances M. Ashcroft
- Department of Physiology, Institute of Neuroscience and Physiology, University of Göteborg
- Patrik Rorsman
- Radcliffe Department of Medicine, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital
- DOI
- https://doi.org/10.1038/s41467-018-08193-8
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 11
Abstract
Impaired glucagon secretion in patients with diabetes causes hypoglycemia. Here the authors show that therapeutic concentrations of insulin inhibit alpha-cell glucagon secretion by stimulating delta-cell insulin receptor and the release of somatostatin. Blocking somatostatin secretion or action ameliorates this effect.
